Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

Fig. 1

ABBV-176 Binding to PRLR. Binding to immobilized PRLR extracellular domain recombinant protein by ELISA is shown in for ABBV-176 and its unconjugated antibody, along with control antibody (unconjugated and PBD-conjugated) to human (A), cynomolgus (B) proteins ECDs. Binding to cells expressing PRLR was assessed by fluorescence activated cell sorting (FACS) analysis of the PRLR-high cell line T47D (C) and the PRLR low cell line MCF-7 (D) with titration curves for geomeans plots shown. Specificity of binding of the anti-PRLR antibody and ABBV-176 is shown in HEK-293 cells engineered to over express PRLR (E) and not in negative control HEK-293 cells (F)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us